Back to Journals » OncoTargets and Therapy » Volume 14

Evaluation of the UK Myeloma Research Alliance Risk Profile in Chinese Patients with Newly Diagnosed Multiple Myeloma without Autologous Stem Cell Transplantation

Authors Ma K, Ye J, Wang L, Sun C, Zhou X

Received 9 January 2021

Accepted for publication 25 February 2021

Published 6 April 2021 Volume 2021:14 Pages 2349—2361

DOI https://doi.org/10.2147/OTT.S300834

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Prof. Dr. Takuya Aoki


Kewa Ma,* Jiannan Ye,* Lingling Wang, Chao Sun, Xin Zhou

Department of Hematology, Affiliated Wuxi People’s Hospital, Nanjing Medical University, Wuxi, Jiangsu, People’s Republic of China

*These authors contributed equally to this work

Correspondence: Chao Sun; Xin Zhou
Department of Hematology, Affiliated Wuxi People’s Hospital, Nanjing Medical University, Wuxi, Jiangsu, 214000, People’s Republic of China
Tel +86-15961806698; +86 51085350201
Fax +86 51085350201
Email [email protected]; [email protected]

Purpose: Recently, the British Myeloma Research Alliance put forward a Myeloma Risk Profile (MRP) for the first time to stratify the prognosis risk of non-transplanted patients with multiple myeloma. However, only limited studies have evaluated the applicability of this model in the Chinese population. This study aimed to estimate the prognostic value of MRP in newly diagnosed multiple myeloma patients without autologous stem cell transplantation in China.
Patients and Methods: Patients with multiple myeloma in Wuxi People’s Hospital from January 1, 2007, to June 30, 2018 were evaluated based on the MRP score, and the relationship between the clinical outcome of patients with MM and the score was analyzed retrospectively.
Results: First, significant differences were observed in the overall survival (OS) (P< 0.05) and progression-free survival (PFS) (P< 0.05) between the low-, middle-, and high-risk groups. Second, in the bortezomib treatment subgroup and complex chromosome karyotype subgroup, OS and PFS were significantly shorter in the high-risk group than in the low-risk group (P< 0.05). Third, the depth of remission still showed prognostic significance in the high-risk MRP group.
Conclusion: MRP is also applicable in Chinese patients with newly diagnosed MM who did not undergo transplantation, as it is simple and cost effective; hence, it is worth popularizing.

Keywords: multiple myeloma, myeloma risk profile, bortezomib, complex chromosome karyotype, prognosis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]